HARVARD BIOSCIENCE INC — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Q2 2026 revenue reached $22.7M (vs. $20.5M YoY), representing 11% growth; H1 2026 revenue $43.5M (vs. $42.2M). Company raised full-year 2026 revenue guidance to 3-5% growth (from prior 1-3%) and maintained adjusted EBITDA guidance at 6-10% growth. Adjusted EBITDA Q2 was $1.7M (vs. $1.5M YoY); H1 adjusted EBITDA $2.4M (vs. $2.3M). CMT and telemetry products drove momentum; gross margin slightly declined to 55.6% (Q2) and 57.2% (H1) due to product/geographic mix. Cash balance declined to $6.5M from $8.6M; net debt increased to $33.5M from $27.9M YoY.
Why this rating
Revenue guidance raise and 11% Q2 growth are operationally positive for this $18.2M market-cap microcap. However, profitability remains negative (GAAP net loss Q2 $2.9M), cash declining, and net debt rising $5.6M YoY—material headwinds. Adjusted EBITDA $1.7M is only ~9% of market cap, thin margin. Moderate relative to company size.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.